PTC Therapeutics, Inc. (PTCT) Stock Overview
Explore PTC Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
PTC Therapeutics, Inc. (PTCT)
Key Financials
Key Financials
Market Cap
6.1B
P/E Ratio
-32.57
EPS (TTM)
$-2.54
ROE
1.00%
PTCT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of PTC Therapeutics, Inc. (PTCT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 51.44, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $86.77.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -32.57 and a market capitalization of 6.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.